Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageTNG456 is a brain-penetrant PRMT5 inhibitor. In May 2025, the first patient was treated with TNG456 in the dose escalation portion of the Phase 1/2 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of TNG456 as a monotherapy. The trial is currently enrolling patients with MTAP-deleted solid tumors, with a focus on GBM. We anticipate providing a safety and efficacy update from this trial in 2026.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Business segments
Q2 2024 · $19.9MThe company’s own SEC segment disclosure.
- License$12.1M61%
- Collaboration$7.8M39%
Tango Therapeutics, Inc. (TNGX) reported revenue of $3.7M in Q2 2026 (quarter ended June 30, 2026), up 17% from the same quarter a year earlier. That came with net loss of $55M. For the full year FY2025, revenue was $62M (+48% year on year) and net income −$102M. Its largest product in 2024-Q2 was License at $12M, 61% of the disclosed total, just ahead of Collaboration at 39%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.